ArticleOpen medicine (Warsaw, Poland)2026
Comprehensive analysis of m6A RNA methylation regulators for prognostic risk stratification and immune microenvironment characterization in colorectal cancer.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Despite mounting evidence of N6-methyladenosine (m6A) dysregulation in colorectal cancer (CRC), comprehensive prognostic association analysis remains limited. We systematically investigated m6A modification patterns and developed a robust risk stratification model. Methods: We analyzed 27 m6A regulators in 488 CRC samples and 42 normal controls from TCGA, with external validation in two independent cohorts (n=762). Consensus clustering identified distinct m6A modification patterns. A prognostic risk model incorporating 268 m6A-associated genes was constructed using multivariate Cox regression. Results: 24 of 27 m6A regulators exhibited significant differential expression (p<0.001). Multivariate analysis identified ZC3H13, LRPPRC, and IGFBP3 as independent prognostic factors. The risk model showed exceptional performance across all validation cohorts (HR: 8.59-14.27, p<0.0001), maintaining significance in early-stage patients. High-risk patients exhibited significantly elevated PD-L1 expression levels (p=5.7 × 10 Conclusions: Our findings reveal pervasive m6A dysregulation with superior predictive performance compared to conventional approaches. The links between RNA methylation and tumor immunity establish m6A signatures as actionable biomarkers for precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.